StockTipsArenaBeta

BUY Morepen Laboratories Limited — Sumeet Bagadia, Choice Broking

BUYMorepen Laboratories Limited
Morepen Laboratories share price target & all analyst calls

bySumeet Bagadia, Choice BrokingHorizon: NA (inferred 1–3 months)16 Aug 2026via LiveMint Buy-or-Sell (topic)

Entry₹84.19Stated
Target₹91.5
Total upside +8.68% (call closed)
Stop loss₹78.5-6.76% risk
Exit₹91.518 Aug 2026, 12:08 pm
Target hit+8.68%0.00%upside left
Follow Sumeet Bagadia for new calls(20% target hit, 41 closed calls)Get alertsWatch MOREPENLAB for new buy/sell callsGet alertsSee 45 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 18 Aug 2026
4 supporting3 neutral0 opposing
Supports the BUY call (4)

Morepen Labs shares jump 9%, snap three-day losing streak; Here's what you need to know

NewsCnbc-Tv18·13 Aug · 5d ago

(opens in new tab)

Morepen Labs Q1 Results: Stock hits 20% upper circuit as CDMO scale-up drives record earnings

NewsCnbc-Tv18·4 Aug · 2w ago

(opens in new tab)

Morepen Laboratories achieved its highest-ever quarterly revenue and earnings in Q1 FY27, with EBITDA growing 207% and PAT by 394%. The CDMO business has entered full-scale commercialization.

NSE · Press Release·4 Aug · 2w ago

(opens in new tab)

Morepen Laboratories reported highest-ever quarterly revenue and earnings in Q1'FY27. EBITDA grew by 207% and PAT by 394%. The company's CDMO mandate entered full-scale commercialization.

BSE · Company Update·4 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (3)

Morepen RX Limited, a wholly-owned subsidiary, has allotted equity shares. The financial impact and details of the allotment are not specified.

BSE · Company Update·6 Aug · 2w ago

(opens in new tab)

Morepen Laboratories Limited announced its un-audited financial results for the quarter ended June 30, 2026. The board also approved the record date for final dividend and extension for hiving off Med

NSE · Outcome of Board Meeting·4 Aug · 2w ago

(opens in new tab)

Morepen Laboratories Ltd has attached the financial results for the first quarter of the financial year 2027.

BSE · Board Meeting·4 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Morepen Laboratories

All analyst calls on Morepen Laboratories

More from Sumeet Bagadia, Choice Broking

Every call and its outcome